Company intelligence / Profile preview
Lundbeck
Valby/Copenhagen area, Denmarklundbeck.com ↗
- Ownership
- Public · HLUN_A
- Employees
- ~5700
- Development stage
- Commercial
01
Overview
Lundbeck has a long history of developing innovative treatments for brain diseases. Its commercial portfolio includes leading drugs such as Rexulti® for schizophrenia/depression/Alzheimer’s agitation and Vyepti® for migraine prevention. Recent clinical results highlight positive data from the PACIFIC trial of bexicaserin in developmental epileptic encephalopathies. Bexicaserin has shown encouraging anti-seizure effects with a differentiated safety profile due to its selective targeting of the serotonin 5‑HT2C receptor. The company continues to expand its neuropsychiatric pipeline through strategic acquisitions like Longboard Pharmaceuticals.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesMonoclonal antibodies (e.g., eptinezumab/Vyepti®)Other biologics and advanced therapies in neuroscience
- Industry
- Biotech
02
Drug pipeline
79 assets78 more assets in the full pipeline.
Request access →03
Partnerships
Notable collaborations with academic institutions via the Grete Lundbeck European Brain Research Foundation (“The Brain Prize”); partnerships may exist with other pharma/biotech companies but specific recent deals are not detailed in search results.
04
Financials
- Market cap
- $50.7B
- Total revenue
- $11.2B
- Enterprise value
- $70.8B
Beyond the preview
Go deeper on Lundbeck.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lundbeck.